Search
Oncolytics Biotech Inc
ONCYAdd to Watchlist
0.899USD
-0.002-0.18%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
104.41MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.18%
5 Days
-2.30%
1 Month
-3.07%
6 Months
-8.60%
Year to Date
+2.87%
1 Year
+14.17%
Key Figures
0.920Open
0.935High
606.98KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.52%Turnover Ratio
0.901Prev. Close
0.871Low
369.59KTurnover
LossP/E Static
-20.07P/B
0.00%Div Yield TTM
-307.78%ROA
1.51052wk High
1.44Volume Ratio
-31.71MNet Profit
116.13MShares
-0.3250EPS TTM
1.03Beta
-769.06%ROE
0.32652wk Low
7.07%Amplitude
--Gross Margin
104.41MMarket Cap
0.42Reward/Risk
5.64%Risk Rate
TradingKey Stock Score of Oncolytics Biotech Inc
Currency: USD Updated: 2026-07-01Key Insights
Oncolytics Biotech Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 172 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.44.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Oncolytics Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Oncolytics Biotech Inc Highlights
StrengthsRisks
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -2.77, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.84M shares, decreasing 51.07% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.58.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
6.438
Target Price
+666.37%
Upside Space
Oncolytics Biotech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Oncolytics Biotech Inc Info
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Ticker SymbolONCY
CompanyOncolytics Biotech Inc
CEOKelly (Jared Ryan)
Websitehttps://www.oncolyticsbiotech.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53072.700
+230.200 (+0.44%)
29429.300
+117.900 (+0.40%)
7499.300
+27.800 (+0.37%)
14810.000
+7.000 (+0.05%)
69006.000
+858.000 (+1.26%)
6371.400
+18.600 (+0.29%)
68.363
+0.019 (+0.03%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4186.170
+64.260 (+1.56%)
FAQs
What is the current price of Oncolytics Biotech Inc (ONCY)?
The current price of Oncolytics Biotech Inc (ONCY) is 0.90.
What is the symbol of Oncolytics Biotech Inc?
The ticker symbol of Oncolytics Biotech Inc is ONCY.
What is the 52-week high of Oncolytics Biotech Inc?
The 52-week high of Oncolytics Biotech Inc is 1.51.
What is the 52-week low of Oncolytics Biotech Inc?
The 52-week low of Oncolytics Biotech Inc is 0.33.
What is the market capitalization of Oncolytics Biotech Inc?
The market capitalization of Oncolytics Biotech Inc is 104.41M.
Is Oncolytics Biotech Inc (ONCY) currently rated as Buy, Hold, or Sell?
According to analysts, Oncolytics Biotech Inc (ONCY) has an overall rating of Buy, with a price target of 6.44.
What is the Earnings Per Share (EPS TTM) of Oncolytics Biotech Inc (ONCY)?
The Earnings Per Share (EPS TTM) of Oncolytics Biotech Inc (ONCY) is -0.31.